Navigation Links
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
Date:1/11/2010

ld senior clinical positions at XOMA, including vice president of clinical science. In addition to overseeing clinical development programs at XOMA, Dr. Garovoy was responsible for managing clinical collaborations with external partners.

"Bavituximab is a promising new approach with broad potential for the treatment of solid cancers and other diseases," said Dr. Garovoy. "Based on the encouraging results seen in early clinical trials, I welcome the opportunity to collaborate with clinical researchers to establish the investigator-sponsored studies that will enhance our understanding of the clinical potential of this exciting new agent."

Dr. Garovoy has authored over 200 medical publications and holds two patents. He held teaching positions as a faculty member at Harvard Medical School and more recently as a Professor of Surgery and Medicine at the University of California, San Francisco. Dr. Garovoy received a BA degree from New York University and an MD degree with honors from the State University of New York Downstate Medical Center. He completed a post-graduate fellowship in Immunology and Transplantation at Harvard Medical School.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results
2. Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
3. Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
4. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
5. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
6. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
8. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
9. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
10. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
11. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Terracon Corporation has announced the introduction of a ... This addition to the company’s industry-leading line of custom ... available in 125 or 250 gallon capacities. It ... or less. , The new pre-engineered TerraPure tank offers ... TerraPure tank line – plus quick turnaround. An ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Beckman ... advances science and healthcare, has renewed its agreement with ... As part of the agreement, Personify will continue to ... sustained emphasis on recruitment analytics, including time-to-fill, time-to-source and ... renew our agreement with Personify was based on the ...
(Date:9/17/2014)... The Pistoia Alliance, a global not ... to innovation in life sciences R&D through pre-competitive ... as Executive Director Business Development North America, as ... , Carmen joins the Pistoia Alliance from Accelrys ... Accelrys, she managed various life sciences and material ...
Breaking Biology Technology:Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... Up in the sky. It's a bird. It's a plane. It's ... denial in a single bound. Indeed, lately the media has been ... to result from the mass exodus of Baby Boomers from the ... believe that this trend and its impacts on businesses are black ...
... Milwaukee, Wis. - The National Cancer Institute ... Medical College of Wisconsin to study the growth ... second successful renewal of the grant that was first awarded ... ongoing principal investigator. , ,She and other investigators are developing ...
... This is the ninth in a series of articles ... sectors. The most recent article focused on worker classification. ... The idea is developed. Lawyers and accountants are on ... is formed. The name has been chosen. Perhaps workers, ...
Cached Biology Technology:Shades of gray: Business impacts of an aging workforce 2Shades of gray: Business impacts of an aging workforce 3Shades of gray: Business impacts of an aging workforce 4Shades of gray: Business impacts of an aging workforce 5Shades of gray: Business impacts of an aging workforce 6Early Stage, Step 9: Raising capital in the securities landscape 2Early Stage, Step 9: Raising capital in the securities landscape 3Early Stage, Step 9: Raising capital in the securities landscape 4
(Date:9/17/2014)... of Spanish researchers have obtained the first partial genome ... century pig found at the site of the Montsoriu ... ancient pig is closely related to today,s Iberian pig. ... crossed with modern Iberian pigs. , The study, published ... aspects of pig species, and particularly on that of ...
(Date:9/17/2014)... in the human retinoblastoma protein gene are a leading ... have turned to fruit fly eyes to unlock the ... a paper featured on the cover of the current ... Michigan State University researchers provide the first detailed examination ... in the human cancer gene, said Irina Pushel, MSU ...
(Date:9/17/2014)... Washington, DC A team of researchers working on a ... that coral growth rates have plummeted 40% since the ... playing an important role in this perilous slowdown. ... peril facing coral reefs, the team compared current measurements ... Great Barrier Reef with similar measurements taken more than ...
Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Abnormal properties of cancer protein revealed in fly eyes 2Coral growth rate plummets in 30-year comparison 2
... and American Board of Internal Medicine (ABIM) announce the ... performance evaluation tools for blood specialists. , ... ABIM certification, ASH and ABIM have co-developed the Hematology ... to complete their practice performance assessment requirement for recertification. ...
... research project which could revolutionise the diagnosis and treatment ... four-year project, the results of which are now being ... means of identifying the two most deadly forms of ... for practitioners. , The implications for improving children's health ...
... to ferns to create a novel energy scavenging device that ... provide a method for powering micro and nano devices with ... works," said Michel Maharbiz, assistant professor of electrical engineering and ... the device. "If you build these things they will move. ...
Cached Biology News:New tool helps blood specialists improve patient care 2Hope for major advance in fighting world killer disease 2Hope for major advance in fighting world killer disease 3Ferns provide model for tiny motors powered by evaporation 2
...
Tissue-Stat ( Tissue Adherent for Mounting Formalin-Fixed and Frozen Tissue Sections.)...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
Biology Products: